Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
Date:3/4/2008

nt associated with our March 2005 financing, as a significant acceleration of the discount took place in 2006 due to the conversion of notes into shares of our common stock.

As of December 31, 2007, we had total cash, cash equivalents and short- term investments on hand of $16.5 million, compared to $24.1 million on hand as of December 31, 2006. The $7.6 million decrease in cash, cash equivalents and short-term investments mainly reflected the use of $25.3 million for operating activities and a $500,000 investment in NAPO, which was partially offset by net proceeds of $17.0 million from an offering of our common stock and warrants to purchase our common stock and $1.0 million from the reduction of an outstanding letter of credit.

Conference Call

To participate in today's 8:30 AM ET live conference call, please dial 800-510-0146 (U.S. callers) or 617-614-3449 (international), and provide passcode 84349393. A live webcast of the call will also be available at: http://phx.corporate-ir.net/playerlink.zhtml?c=122332&s=wm&e=1768582. Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days beginning today at 10:30 AM ET at 888- 286-8010 (U.S. callers) or 617-801-6888 (international callers), using passcode 90757979.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Sec
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
2. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
3. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed to Appeal Delisting Notification From Nasdaq
6. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
7. Insmed Appoints Dennis M. Lanfear to Board Of Directors
8. Barr Announces Favorable Ruling in Yasmin(R) Patent Challenge
9. Vermillion Announces Effectiveness of Reverse Stock Split
10. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
11. ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Francisco, CA (PRWEB) May 21, 2015 ... sequencing, has announced a partnership with PicnicHealth, a ... for patients. Participants diagnosed with Inflammatory Bowel Disease ... well as a complementary uBiome research kit. Both ... 2014. , For more information ...
(Date:5/21/2015)... LONDON , May 21, 2015 ... your inner feelings - and those of others. Being ... and senses. Analyze and read people to anticipate their ... your deepest emotions and feelings to create unique ... generation of responsive games. Get inside a first-person-shooter as ...
(Date:5/21/2015)... 21, 2015 Patent Offering, The patent’s ... diagnostic or therapeutic imaging within a body lumen (open ... endoscope having a low cost, single-use disposable illumination and ... was October 18, 2013 and the patent approval was ... the physician to customize the lighting and magnification of ...
(Date:5/21/2015)... As part of its philanthropic partnership ... Health Foundation funded a $3.25 million project to relocate ... the most up-to-date features and technology. , The new ... 45 staff members will begin moving from the current ... coming days. , The current pharmacy has been ...
Breaking Biology Technology:uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 35 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3
... Sept. 10 Signalife, Inc. (Amex:,SGN) announced that the company,s ... stock to be effected in the form of a,reverse stock ... on September,19, 2008, which will be the record date and ... time of such reverse stock split, all,outstanding shares of Signalife ...
... 10 , - Abstracts 185 and 1112, ... announced results from,two randomized clinical studies presented at ... 44th Annual Meeting demonstrating that the,"basal plus" insulin ... daily (basal insulin) and APIDRA(R) once daily,(prandial insulin) ...
... Sept. 10 Abeome Corporation, a,Georgia-based biotech company, ... (SAB) to collaborate on the development of,Abeome,s ovarian ... therapeutic,and diagnostic projects for the company., The ... Meagher, PhD, Chief,Scientific Officer for Abeome, Distinguished Research ...
Cached Biology Technology:Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 2Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 3Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 4Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 5Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 6Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 2Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 3Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 4Abeome Forms First Class Scientific Advisory Board 2
(Date:5/22/2015)... 22, 2015 According to a ... (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), by ... Utilities, Consumer and Home) - Global Forecast to 2020", ... $2.77 Billion in 2015 to $6.19 Billion by 2020, ... 79 market data Tables and   43 Figures spread ...
(Date:5/19/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... 2, 2013  Fingerprint Cards, swipe sensor ... well-renowned Asian OEM customer for an additional smartphone scheduled to be launched ... Fingerprint Cards (FPC) has earlier announced multiple mobile and tablet DWs ... Korea, with the first phones in Japan and ...
... is a bacterium that establishes a life-long stomach infection in ... or stomach cancer. New research, presented at this week,s Society ... of how these bacteria can manipulate the human immune system ... Researchers from the University of Nottingham have shown that ...
... the world have watched as strain after strain of the ... Over the last few decades researchers have used ... individual mutations that allow TB to withstand many of the ... markers serve as clues for new drug development and as ...
Cached Biology News:FPC Awarded new Smartphone DW From Existing Prominent Asian OEM Customer for Launch With Leading US Operator 2Stomach bacteria switch off human immune defences to cause disease 2Researchers untangle genetics of drug resistant TB 2Researchers untangle genetics of drug resistant TB 3Researchers untangle genetics of drug resistant TB 4
Request Info...
... Antibody Epitope: aa 16-25 of human ... Recommended Storage: Store vial at -20 C ... For extended storage aliquot contents and freeze at -20 C ... Family: Other Sub-Family: ...
... Physical form: Essentially sulfate-free, powder ... Preparation Unit Definition: One ... D -fructose 6-phosphate to ... pH 7.4 at 25 C. ...
... Blasticidin is a nucleoside ... It is a potent ... prokaryotic and eukaryotic cells. ... conferred by the products ...
Biology Products: